Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists.
J Pharmacol Exp Ther. 2006 Nov;319(2):765-75. doi: 10.1124/jpet.106.107987. Epub 2006 Aug 1.
J Pharmacol Exp Ther. 2006.
PMID: 16882876